Targeting the CD38-NAD⁺ axis alleviates antibody-driven cytopenia in autoimmune disorders without inducing broad immunosuppression

作者
Hui Li,Lei Zhang
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 4793-4793 被引量:1
标识
DOI:10.1182/blood-2025-4793
摘要

Abstract Autoimmune diseases, including immune thrombocytopenia (ITP), are typically managed through long-term non-specific immunosuppression with limited efficacy and safety. Our previous research has shown that anti-CD38 monoclonal antibody (mAb) therapy rapidly restores platelet counts in patients with refractory ITP, although the underlying mechanism remains unknown. Here, we report that anti-CD38 mAbs induce rapid elevation in platelet counts within 3 days of administration, even upon re-treatment in relapsed cases. Using passive ITP models with CD38 knockout mice and immune cell-specific depletion, we identified CD38-driven NAD⁺ depletion as a key immunometabolic checkpoint that promote pro-inflammatory macrophage polarization and platelet destruction. Supporting these findings, immunofluorescence, single-cell transcriptomic, and proteomic analyses of spleens and peripheral blood samples from ITP patients confirmed that anti-CD38 mAb therapy reversed aberrant macrophage polarization. Consistently, modulation of NAD⁺ metabolism through genetic deletion or pharmacological inhibition of CD38, or supplementation with nicotinamide mononucleotide (NMN), reprograms macrophage polarization and prevents thrombocytopenia in mice. Complementing these preclinical findings, a first-in-human trial demonstrated that low-dose NMN rapidly restores platelet counts within 3 days, with only 2 in 25 patients experiencing grade 1 infections which may attributable to preserved plasma cell numbers and immunoglobin levels. Together, these findings establish the CD38-NAD⁺ axis as a key immunometabolic driver of autoantibody-mediated cytopenia and introduce a novel therapeutic paradigm for antibody-mediated autoimmune disorders centered on targeted macrophage metabolic modulation rather than pan-B cell or plasma cell depletion, representing a promising and transformative resolution to the long-standing trade-off between therapeutic efficacy and broad immunosuppression (ClinicalTrials.gov: NCT06776510).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Lucas的应助被嘎嘎的鸡神采纳,获得10
1秒前
iso发布了新的文献求助10
2秒前
psj发布了新的文献求助10
2秒前
海鹏发布了新的文献求助10
2秒前
威武诺言发布了新的文献求助10
2秒前
3秒前
3秒前
念明完成签到,获得积分10
4秒前
科研狗发布了新的文献求助20
4秒前
5秒前
5秒前
5秒前
5秒前
twistzz发布了新的文献求助10
5秒前
6秒前
sszz发布了新的文献求助10
6秒前
科研通AI6.3的应助被李亚楠采纳,获得10
6秒前
英姑的应助被Tayzon采纳,获得10
7秒前
zt发布了新的文献求助10
8秒前
百里一一完成签到,获得积分10
8秒前
西北一枝花发布了新的文献求助100
8秒前
Lucas的应助被qifei采纳,获得10
8秒前
CipherSage的应助被梦回采纳,获得30
8秒前
9秒前
9秒前
Hello的应助被yuan采纳,获得20
9秒前
9秒前
tanrui完成签到,获得积分10
9秒前
完美芯发布了新的文献求助10
11秒前
Ava的应助被ai采纳,获得10
11秒前
CarryLJR的应助被邓惠文采纳,获得10
12秒前
多情凡雁发布了新的文献求助30
12秒前
李亚楠完成签到,获得积分20
13秒前
春天完成签到,获得积分10
13秒前
超级冬瓜完成签到,获得积分20
14秒前
希望天下0贩的0的应助被4rcanist采纳,获得10
15秒前
15秒前
sunnymoon的应助被小萌兽采纳,获得50
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178582
求助须知:如何正确求助?哪些是违规求助? 9569391
关于积分的说明 21804062
捐赠科研通 7773535
什么是DOI,文献DOI怎么找? 3432871
关于科研通互助平台的介绍 2556860
邀请新用户注册赠送积分活动 2478451